Post-intervention minimal stent area as a predictor of target lesion revascularization after everolimus-eluting stent implantation for in-stent restenosis: a single-center observational study.
暂无分享,去创建一个
Takeshi Kimura | T. Morimoto | T. Takeda | H. Mabuchi | T. Murakami | T. Sakaguchi | Masayuki Yamaji | K. Maeda | Noriyuki Takashima | Takanari Fujita | Yoshifumi Hano | Y. Hano
[1] Seung‐Jung Park,et al. Meta-analysis of outcomes after intravascular ultrasound-guided versus angiography-guided drug-eluting stent implantation in 26,503 patients enrolled in three randomized trials and 14 observational studies. , 2014, The American journal of cardiology.
[3] A. Íñiguez,et al. A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: the RIBS V Clinical Trial (Restenosis Intra-stent of Bare Metal Stents: paclitaxel-eluting balloon vs. everolimus-eluting stent). , 2014, Journal of the American College of Cardiology.
[4] Seung‐Jung Park,et al. Intravascular ultrasound assessment of optimal stent area to prevent in‐stent restenosis after zotarolimus‐, everolimus‐, and sirolimus‐eluting stent implantation , 2014, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[5] B. García del Blanco,et al. 3-Year Clinical Follow-Up of the RIBS IV Clinical Trial: A Prospective Randomized Study of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis in Coronary Arteries Previously Treated With Drug-Eluting Stents. , 2018, JACC. Cardiovascular interventions.
[6] G. Stone,et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. , 1999, Circulation.
[7] Helmut Baumgartner,et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous , 2014, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[8] G. Lemesle,et al. Outcome differences with the use of drug-eluting stents for the treatment of in-stent restenosis of bare-metal stents versus drug-eluting stents. , 2009, The American journal of cardiology.
[9] P. Serruys,et al. Reference chart derived from post-stent-implantation intravascular ultrasound predictors of 6-month expected restenosis on quantitative coronary angiography. , 1999, Circulation.
[10] Seung‐Jung Park,et al. Mechanisms of In-Stent Restenosis After Drug-Eluting Stent Implantation: Intravascular Ultrasound Analysis , 2011, Circulation. Cardiovascular interventions.
[11] C. Tracy,et al. American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. , 2001, Journal of the American College of Cardiology.
[12] Peter L Duffy,et al. Relationship Between Intravascular Ultrasound Guidance and Clinical Outcomes After Drug-Eluting Stents: The ADAPT-DES Study , 2013 .
[13] A. Kastrati,et al. Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial , 2013, The Lancet.
[14] Fernando Alfonso,et al. Current treatment of in-stent restenosis. , 2014, Journal of the American College of Cardiology.
[15] Helmut Baumgartner,et al. ESC / EACTS Guidelines on myocardial revascularization , 2014 .
[16] A. Kastrati,et al. Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis , 2015, The Lancet.
[17] T. Ryan. Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). , 1988, Journal of the American College of Cardiology.
[18] P. Fitzgerald,et al. Impact of final stent dimensions on long-term results following sirolimus-eluting stent implantation: serial intravascular ultrasound analysis from the sirius trial. , 2004, Journal of the American College of Cardiology.
[19] Y. Hayashi,et al. A multicenter randomized comparison of paclitaxel-coated balloon catheter with conventional balloon angioplasty in patients with bare-metal stent restenosis and drug-eluting stent restenosis. , 2013, American heart journal.
[20] A. Íñiguez,et al. A Prospective Randomized Trial of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis of Drug-Eluting Stents: The RIBS IV Randomized Clinical Trial. , 2015, Journal of the American College of Cardiology.
[21] J. Fajadet,et al. One-year results of the CRISTAL Trial, a randomized comparison of cypher sirolimus-eluting coronary stents versus balloon angioplasty for restenosis of drug-eluting stents. , 2012, Journal of interventional cardiology.
[22] B. García del Blanco,et al. Long-Term Results of Everolimus-Eluting Stents Versus Drug-Eluting Balloons in Patients With Bare-Metal In-Stent Restenosis: 3-Year Follow-Up of the RIBS V Clinical Trial. , 2016, JACC. Cardiovascular interventions.
[23] Volkmar Falk,et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Ca , 2014, European heart journal.